BioCentury
ARTICLE | Company News

Sepracor submits NDA for broader application

April 16, 2001 7:00 AM UTC

SEPR partner Schering-Plough (SGP) submitted an NDA to the FDA for a broader indication of Clarinex desloratadine 5 mg tablets to treat perennial allergic rhinitis (PAR) and seasonal allergic rhinitis...